Direct2Attorney is a legal marketing & referral service, not a law firm and not a substitute for legal advice.
Home / Mass Tort / Dupixent Lawsuit
A Dupixent lawsuit may be an option if a skin cancer followed your treatment. For years it was just eczema. Creams, steroids, and doctors telling you to moisturize more. Then came Dupixent, and for a while things got better.
But the rash came back different. Thicker. In patches that would not go. Then a biopsy nobody expected came back with a word you had never heard: lymphoma. A participating law firm may review your claim for free.
Diagnosed with CTCL on Dupixent?
About 2 minutes · free · private
Eligibility
You may qualify if these describe you or someone you love. These are the guidelines participating law firms use when they review a Dupixent claim. For official background, see the MedlinePlus drug information on Dupixent (dupilumab).
Most claims involve eczema, but the drug is also approved for asthma, nasal polyps, eosinophilic esophagitis, prurigo nodularis, and COPD.
Cutaneous T-cell lymphoma, mycosis fungoides, or Sézary syndrome. The diagnosis should be confirmed by a skin biopsy.
The timeline matters more than anything else in these cases. A firm will map when you started, how long you took it, and when the biopsy happened.
A rash that spread, thickened, turned into patches or plaques, or stopped responding, especially after an early period of improvement.
Some claims are not about the drug causing cancer at all. They are about symptoms being eased while an undiagnosed lymphoma kept growing.
A spouse, child or estate representative may be able to bring a wrongful death claim. These deadlines usually start on the date of death.
Think it was partly your fault?
Most states still allow recovery, reduced by your share of the blame. It is one of the most common reasons people never call, and one of the least justified.
Meeting these guidelines does not mean you have a valid claim. It means a participating law firm is likely to review it. That firm decides on its own whether to take your case. Some claims are turned down, and some recover nothing. Direct2Attorney cannot judge the legal merits of your case, give legal advice, or file anything for you.
Before you decide
Most people who could ask for a review never do. These are the usual reasons, and what is true.
What holds people back
Some people fear a claim will change their treatment.
What is true
Your treatment is between you and your doctor. Asking a lawyer is a completely separate question. Do not stop Dupixent on your own.
What holds people back
Many people assume that rules them out.
What is true
One of the main theories is that the drug eased the symptoms of a hidden lymphoma and delayed the biopsy that would have found it.
What holds people back
Dermatology notes span years and many offices.
What is true
Pharmacy, dermatology and pathology records hold the dates that decide these cases. You only need to share what you remember to start.
What holds people back
Lawsuits sound expensive.
What is true
Participating firms work on contingency. No recovery, no attorney fee.
About the drug
Read this first: do not stop taking Dupixent on your own. Dupixent works well for millions of people. Stopping it suddenly can cause a severe skin flare. For someone using it for asthma, stopping can be dangerous. Nothing on this page is medical advice, and nothing here is a reason to skip a dose. If this page worries you, call your prescribing doctor and ask. That is a medical decision between you and your physician. It is completely separate from any legal question, and asking a lawyer never changes your treatment.
Dupixent is the brand name for dupilumab. It is a biologic, made by Sanofi and Regeneron and approved in 2017. It works by blocking two proteins in the immune system called IL-4 and IL-13, which drive the inflammation behind eczema and several other conditions.
The lawsuits are about a rare skin cancer called cutaneous T-cell lymphoma, or CTCL. CTCL is a cancer of white blood cells that appears in the skin. The most common type is mycosis fungoides. A more advanced type is Sézary syndrome.
Here is the part that matters. In its early stages, CTCL looks almost exactly like eczema. Red, itchy, scaly patches. It is routinely mistaken for eczema for years. Diagnosis usually comes only from a skin biopsy.
Three different claims, not one
The drug caused it
Suppressing part of the immune system allowed a T-cell cancer to develop.
The drug hid it
The lymphoma was already there. The drug eased the rash, so nobody ordered the biopsy.
The drug made it worse
In patients who already had CTCL, the drug sped it up.
All three theories share the same legal core: that Sanofi and Regeneron should have warned patients and doctors about the risk, and did not.
Here is the defense argument, and it is a real one. Early CTCL looks like eczema that will not respond to anything. Patients with stubborn eczema are exactly the ones who get prescribed a biologic. So people who later turn out to have CTCL were more likely to be put on Dupixent in the first place.
| Approved use | What to know |
|---|---|
| Eczema (atopic dermatitis) | Most claims involve eczema patients |
| Asthma | Stopping suddenly can be dangerous; talk to your doctor |
| Nasal polyps | Also an approved use |
| Eosinophilic esophagitis | Also an approved use |
| Prurigo nodularis | Also an approved use |
| COPD | Also an approved use |
Drug and company names are used only to identify the product at issue. Direct2Attorney is not affiliated with, endorsed by, or sponsored by Sanofi, Regeneron, the FDA, or any court.
The medical side, in plain words
CTCL is rare and slow. That is exactly why it is so easy to miss. Here is how it happens, in plain words.
Early CTCL shows up as red, itchy, scaly patches. Doctors and patients often see it as one more eczema flare.
CTCL is a cancer of T-cells, a kind of white blood cell. Instead of staying in the blood, the cells gather in the skin.
If a drug calms the rash, nobody looks closer. The claims say that is how a biopsy gets delayed.
A small skin sample, read by a pathologist, is usually the only way to tell CTCL apart from eczema.
Changes after improving at first
Many people in these cases say Dupixent helped at first, then the rash came back different. If your rash is changing, ask your dermatologist whether a skin biopsy is appropriate.
Treatment
Treatment depends on the stage. Many people live for years with early CTCL. Each step also leaves a record, and those records later show what the illness cost you.
General information only, not medical advice. Your care team decides your treatment. Do not stop or change Dupixent based on what you read here.
Finding it
A biopsy confirms CTCL. Blood tests and scans show how far it has spread.
Early stage
Creams, gels and other treatments put directly on the patches.
Light therapy
Controlled ultraviolet light, often given several times a week.
Targeted care
Used on stubborn spots or across the whole skin surface.
Advanced disease
Medicines that treat the whole body and, in some cases, a stem cell transplant.
Ongoing
Regular visits with dermatology and oncology to watch for changes.
Quick self-check
If you can say yes to most of these, it is worth asking for a free review.
Did you take Dupixent for eczema, asthma or another condition?
Were you diagnosed with CTCL, mycosis fungoides or Sézary syndrome?
Was the lymphoma found after you started Dupixent?
Was the diagnosis confirmed by a skin biopsy?
Requirements
You do not need any of this to start. A firm collects it for you. But every claim is built on these four things.
Proof of use
Pharmacy records showing Dupixent.
Proof of diagnosis
A biopsy and pathology report.
A clear timeline
Dermatology notes from before and after.
Filed in time
Each state sets its own deadline.
Case status
Federal cases are grouped as MDL No. 3180, In re: Dupixent (Dupilumab) Products Liability Litigation, in the District of New Jersey before Judge Zahid N. Quraishi. This is a very new litigation.
Ignore the payout figures online
There is no Dupixent lawsuit settlement, no trial date and no verdict. Any dollar figure quoted for a Dupixent claim is a guess. Sanofi and Regeneron dispute causation entirely, and no court has found them liable.
Dupixent approved
The FDA approves Dupixent for eczema. More uses follow.
MDL 3180 created
Federal cases are centralized in New Jersey. The litigation began with 15 cases from 12 districts, plus 7 possible tag-along actions.
38 cases pending
The federal court panel’s monthly report lists 38 actions pending in MDL 3180.
Early stage
The court is setting its early schedule. Firms are still accepting new cases. No trial date has been set.
This is not medical advice. If you are on Dupixent and your rash is changing, spreading, thickening, forming raised patches, or not responding the way it used to, tell your dermatologist and ask whether a skin biopsy is appropriate. Do not stop or change treatment based on what you read here.
Compensation
If a claim succeeds, compensation is meant to cover what the illness has cost you, in money, in work, and in life. Here is what these claims typically seek.
No one can tell you what your claim is worth before reviewing your records, and no one can promise you will recover anything at all. Past results do not guarantee or predict a similar outcome in any future case.
The process
You do not need your records or exact dates to start a Dupixent lawsuit review. Tell us what you remember and the firm does the rest.
Fill out the short form or call. What you took Dupixent for, roughly when you started, and what you were diagnosed with. No cost and no obligation.
If your situation fits, we connect you with a participating law firm. That firm decides on its own whether to represent you. If it does, you sign an agreement directly with the firm.
Dermatology notes, pharmacy records, biopsy and pathology reports. In these cases the timeline is the case, and pathology review often decides whether a firm takes it.
Your Dupixent lawsuit is filed and coordinated in MDL 3180. Your firm keeps you updated as the court sets its schedule. You never have to accept an offer you do not want.
READY WHEN YOU ARE
Step 1 takes about two minutes.
Why people use us
No upfront fees
The review is free. Participating firms work on contingency, so a fee is owed only out of a recovery. No recovery, no attorney fee.
Firms in this MDL
We connect you with firms handling pharmaceutical claims, ones already filing into MDL 3180 and following the court’s early schedule.
We help with records
Dermatology and pharmacy records hold the dates that decide these cases. A firm can request them for you.
Private and secure
Your information is encrypted and handled according to our Privacy Policy. You are never obligated to move forward.
What Direct2Attorney is
A legal marketing and referral service. We check whether your situation matches what participating law firms are looking for, and connect you with one of them if it does.
What Direct2Attorney is not
We are not a law firm. We cannot give you legal advice, represent you, or file anything on your behalf. Only a law firm you sign with can do that.
Firms are reviewing new Dupixent claims
Did you take Dupixent and later get diagnosed with cutaneous T-cell lymphoma, mycosis fungoides or Sézary syndrome? Find out whether a Dupixent lawsuit is open to you. It takes about two minutes and costs nothing. Your state’s filing deadline is running whether or not you look into it, and asking a lawyer never changes your medical treatment.
What happens after you ask
We check your answers
Usually the same business day
A participating firm may call you
At the time you choose
You decide what comes next
No cost and no obligation, ever
Questions
Still have a question? Ask it on the call. The review is free, and there is no obligation.
Start my free review →Participating law firms are generally reviewing claims from people who took Dupixent and were later diagnosed with cutaneous T-cell lymphoma, mycosis fungoides or Sézary syndrome. The diagnosis usually needs to come after starting the drug and be confirmed by a skin biopsy. Family members may be able to bring a wrongful death claim for a loved one who died.
Do not stop on your own. Dupixent controls serious conditions for millions of people, and stopping suddenly can cause severe flares or, for asthma patients, a dangerous attack. Nothing on this page is medical advice. If you are worried, call your prescribing doctor and ask. That is a medical decision between you and your physician, and it is completely separate from any legal question.
Cutaneous T-cell lymphoma, or CTCL, is a rare cancer of white blood cells that shows up in the skin. The most common form is mycosis fungoides. A more advanced form is Sézary syndrome. In its early stages CTCL can look almost exactly like eczema, which is why it is often misdiagnosed for years before a skin biopsy identifies it.
On June 4, 2026 federal cases were centralized into MDL No. 3180, In re: Dupixent (Dupilumab) Products Liability Litigation, in the District of New Jersey before Judge Zahid N. Quraishi. The litigation began with 15 cases from 12 districts plus 7 potential tag-along actions. There is no settlement, no trial date and no verdict. This is a very new litigation.
Update: the Judicial Panel on Multidistrict Litigation’s report of October 1, 2026 lists 38 actions pending in MDL 3180. There was still no settlement, trial date or verdict as of October 3, 2026.
That may still support a claim, and it is one of the main arguments in this litigation. Early CTCL looks like stubborn eczema, so some patients were treated with Dupixent when the cancer was already present but undiagnosed. Claims argue the drug eased the symptoms while the disease kept progressing, delaying the biopsy that would have found it. A firm reviewing your records looks at the timeline either way.
Nothing to ask. The case review is free with no obligation. If a participating law firm takes your case, it will normally work on contingency. That means the fee comes out of a recovery, and no fee is owed if there is no recovery.
No. Direct2Attorney is a legal marketing and referral service, not a law firm. An attorney-client relationship may form only after a participating law firm reviews your information and signs a separate representation agreement with you.
Yes. Most claims involve eczema, but Dupixent is also approved for asthma, nasal polyps, eosinophilic esophagitis, prurigo nodularis and COPD. What matters is the diagnosis and the timeline, not the reason you were prescribed it.
In the news
Plain-English articles from our editorial team on the latest rulings, trials and deadlines, and what each one means if you are thinking about a claim.
Official resources
